Gyrolab xPlore™ immunoassay system

Discover how the Gyrolab® transforms immunoassay workflows by automating ELISA, cutting sample and reagent usage, and delivering results up to four times faster, boosting productivity and data quality in bioprocessing and bioanalysis.

In this white paper, Gyros Protein Technologies discusses the crucial role of immunoassay platforms in ensuring the timely release of safe and effective cell and gene therapeutics. Choosing the right platform involves considering various factors, including robustness, quick data generation from limited samples, support for rapid method development, and flexibility for novel assays. Automation and walk-away systems are essential for reducing manual labor and minimizing errors, allowing personnel to focus on more critical tasks. Additionally, ready validation and software that enables 21 CFR Part 11 compliance are necessary to meet regulatory guidelines.

In this white paper, Gyros Protein Technologies illustrates the contribution of automated flow-through microfluidic immunoassays using Gyrolab system in generating reliable data for applications in public health and the development of vaccines and antibody-based treatments.

The drive to generate preclinical and clinical data from smaller volumes of precious sample has led to considerable developments in sampling methods, In this white paper Gyros Protein Technologies describe the most common methods used for microsampling and their respective advantages and disadvantages, how microsampling is being used in preclinical and clinical studies as well as in diagnostics. Download the white paper below to find out a whole host of biopharmaceutical implications via microsampling.

Building on advances in microfluidics, next-generation immunoassays offer unparalleled capability in automation and miniaturization, generating robust and reproducible results for faster decision-making.

In this eBook, discover the advantages of automated, miniaturized immunoassays across the drug development pathway, from pre-clinical to bioprocessing. Learn about challenges and trends in immunoassay technology and how automated, miniaturized immunoassays can help you maximize productivity across a range of biopharmaceutical applications, including:

• Research and clinical development
• Insulin quantification
• Anti-drug antibody studies
• In-solution affinity determination
• Vaccine development and production
  

In this white paper, Gyros Protein Technologies demonstrates how high-quality reagents from Sino Biological can be used in a high-performance, one-hour microfluidic, nanoliterscale immunoassay using Gyrolab® platform for the qualitative detection of total antibodies generated against the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 in human serum samples.

Download it below to explore details of the miniaturized, microfluidic SARS-CoV-2 antibody immunoassay development and learn more about the future directions for Gyrolab assay development to detect SARS-CoV-2 antibodies.

Friday, March 27 at 16:00 GMT | 17:00 CET | 12:00 EDT | 09:00 PDT

As bioanalysis demands continue to rise, driven by expanding study portfolios, accelerated timelines, and fluctuating project volumes, CROs and pharmaceutical organizations are under increasing pressure to scale efficiently while maintaining regulatory‑ready data quality. Automation is becoming essential for meeting these expectations, enabling teams to increase throughput without adding operational complexity or additional headcount.

This SelectScience® TechTalk brings together valuable CRO insight from an expert working at the forefront of modern bioanalysis: Jason McGraw, Application Scientist, Charles River Laboratories. He will discuss how automated Gyrolab® immunoassay workflows are being implemented to boost productivity, reduce hands‑on time, and deliver consistent pharmacokinetics (PK) data across diverse study types.

In just 20 minutes, attendees will gain practical guidance on how automation is reshaping bioanalytical operations, supporting flexible scaling and helping teams meet rising regulatory expectations in today’s demanding scientific environment.

Key learning objectives:

• Gain insight into real-world implementation of Gyrolab immunoassay systems in a CRO environment.
• Understand how automated Gyrolab workflows support high-throughput bioanalysis without increasing operational complexity.
• Learn how CROs manage variable study volumes and aggressive timelines using standardized, automated assays.
• Explore strategies to reduce hands-on time and analyst variability while maintaining data quality and reproducibility.
• Identify opportunities to improve resource efficiency and turnaround times in PK bioanalysis.

Who should attend?

• Bioanalytical and DMPK leadership, including heads of bioanalysis/PK/DMPK, CRO scientific and operational directors, and laboratory leads in pharma and CROs
• Hands‑on bioanalytical innovators, including bioanalytical scientists, assay development and method transfer teams, laboratory automation leaders, and project managers overseeing bioanalytical timelines

Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.

TechTalk details

• Cost: Free to attend
• Location: Online
• Duration: 20 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available

Gyros Protein Technologies is driven by a clear mission: to accelerate drug development by miniaturizing ligand binding assays so scientists can do more with less. This focus on productivity and efficiency underpins the development of tools that help researchers overcome challenges such as limited sample volumes and tight timelines. The GyroLab xPlore™ exemplifies this approach, delivering an end‑to‑end workflow in an hour. In this SelectScience interview, hear from Senior Field Application Scientist Eric Feely, as he discusses how the team continues to advance automation technologies and collaborate with automation groups to further streamline and accelerate laboratory workflows.

This video was filmed at SLAS 2026.

Advance gene therapy precision by reliably testing pre-existing AAV immunogenicity

Find out how Custom Assay Services from Gyros Protein Technologies accelerate biotherapeutic development

Watch exclusive interviews with industry experts on the key to vaccine development success, the role of biomaterials in creating drug models, and more

Explore the latest application eBooks with top tips on biopharmaceutical characterization and high-content screening

Johan Engström, Senior Scientist at Gyros Protein Technologies, discusses the challenges of measuring high-affinity interactions of ligands in cancer immunotherapy

Guest editorial: Technology to meet the challenge of efficiency in the regulated AAV vector space

EMD Serono senior scientist Carina Carter shares her experience with some of the latest immunoassay technology optimizing pharmacokinetics and immunogenicity assay development

Guest editorial: Technology to meet the needs of faster vaccine development